Hantavirus vaccine could be ready in 100 days, but funding gaps remain

Quick summary

European researchers could develop an RNA-based hantavirus vaccine within 100 days, potentially outperforming existing South Korean and Chinese vaccines, but human trial funding remains a critical barrier despite Moderna's expressed interest.

Why it matters

If hantavirus cases continue rising across Europe, delayed vaccine funding could leave you and your region vulnerable to an infection with high mortality rates and no reliable preventive option, while the technology exists but remains stalled at the funding stage.

Key takeaways

• ›European researchers are developing an RNA vaccine that could be ready in 100 days, using the same technology platform that worked for COVID-19.
• ›South Korea and China already have hantavirus vaccines but they show limited effectiveness, creating demand for a better alternative.
• ›Human trial funding is currently unavailable, making this the critical bottleneck for the vaccine's development.
• ›Moderna has signaled interest in supporting the project, potentially unlocking the financing needed to proceed.